ABBV
AbbVie Common Stock
Position levels
Currenttoday
USD 250.94
Buy <=wait / entry
USD 211.67
Trim >=take some off
USD 255.00
Thesis breakA material Skyrizi or Rinvoq execution setback (such as a negative label update,...
-
Scenario-weighted conviction
| Probability | Score | Contribution | |
|---|---|---|---|
| Bull case | 19% | 100 / 100 | 19.0 |
| Base case | 50% | 62 / 100 | 31.0 |
| Bear case | 31% | 10 / 100 | 3.1 |
| Weighted conviction | 53 / 100 - OPPORTUNISTIC BUY | ||
Top risks
- M&A activity: AbbVie to acquire Apogee Therapeutics for $10.9 billion equity value, adding pipeline assets including zumilokibart (APG777) for atopic dermatitis and APG273 for asthma
- Earnings beat: Q2 2026 GAAP diluted EPS $2.03 (up 290.4%) and adjusted diluted EPS $3.65 (up 22.9%), with net revenues of $16.99 billion (up 10.2% YoY) beating expectations
- Immunology portfolio momentum: Skyrizi and Rinvoq delivered strong revenue growth in Q2